Johnson & Johnson Innovation - JJDC

Johnson & Johnson Innovation - JJDC, established in 1973 and based in New Brunswick, New Jersey, serves as the corporate venture capital arm of Johnson & Johnson. The organization focuses on accelerating early-stage innovation by fostering strategic collaborations. JJDC connects potential partners with essential resources to support advancements in transformation science and technology across various sectors, including pharmaceuticals, medical devices, consumer healthcare, and medtech. Through its investment activities, JJDC aims to drive innovation and enhance the development of new solutions that can improve health and well-being.

Kadir Kadhiresan Ph.D

Vice President, Venture Investments

Fiona MacLaughlin Ph.D

Principal, Venture Investments

Tamir Meiri

Principal, Venture Investments

Sanjay Mistry Ph.D

Vice President, Venture Investments, New Company Creation

Marian Nakada Ph.D

Vice President, Venture Investments

Asha Nayak Ph.D

Vice President, Consumer Health Investments

Hirak Parikh

Principal, Venture Investments

Chris Picariello

President

Elizabeth Wu Ph.D

Director, Early Innovation Partnering

Wei Wu Ph.D

Principal, Venture Investments

Asish Xavier

Vice President, Venture Investments

105 past transactions

Prazer Therapeutics

Series B in 2025
Prazer Therapeutics is a biotechnology company dedicated to developing novel therapeutics for patients suffering from intractable diseases, particularly focusing on neurodegenerative and refractory inflammatory conditions. The company employs innovative drug design approaches, including rational molecular drug design and next-generation protein degradation technology, to create effective treatments. By leveraging these advanced platforms, Prazer Therapeutics aims to address significant unmet medical needs and enhance the treatment landscape for challenging health issues.

Perceive Pharma

Series A in 2025
Perceive Pharma operates as a pharmaceutical company. Perceive Pharma develops innovative small molecule neuroprotective treatments.

TECLens

Series A in 2025
TECLens, LLC is a development stage company based in St. James, New York, focused on designing and manufacturing medical contact lenses for myopia treatment. Established in 2013, the company has developed a non-invasive therapy involving the use of its product, the CXLens (Corneal Crosslinking Lens), which is worn for just half an hour in a doctor's office. This innovative lens features real-time ultrasound sensing and a high oxygen concentration environment to ensure precise targeting and stability during treatment. TECLens aims to address various vision issues, including progressive myopia in children and vision problems in adults, such as hyperopia and low-order myopia. Its technology is designed to improve patients' eye health and potentially reduce the long-term risks associated with traditional corrective lenses.

Cala Health

Series C in 2024
Cala Health, Inc. is a bioelectronic medicine company based in Burlingame, California, founded in 2013. It specializes in developing wearable neuromodulation therapies aimed at treating chronic diseases. The company's flagship product, Cala Trio, is a non-invasive prescription therapy designed to provide transient relief from hand tremors in adults with essential tremor. By integrating advancements in neuroscience and technology, Cala Health focuses on delivering individualized peripheral nerve stimulation. In addition to its work on essential tremor, the company is also developing therapies for other neurological conditions, including Parkinson's disease, as well as applications in psychiatry, cardiology, and autoimmune disorders.

Citryll

Series B in 2024
Citryll is a private pharmaceutical company based in Oss, The Netherlands, founded in 2015. The company focuses on developing drugs aimed at treating autoimmune diseases and other human health conditions. Citryll's innovative approach involves the manipulation of the formation, function, and clearance of neutrophil extracellular traps (NETs) that are influenced by the protein citrullination pathway, specifically through the action of Peptidylarginine Deiminase (PAD) enzymes. This research supports medical professionals in addressing various serious conditions, including lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis, and organ damage resulting from sepsis.

G.I. Windows

Series B in 2024
G.I. Windows, Inc. is a clinical-stage company based in West Bridgewater, Massachusetts, specializing in the manufacture of medical devices that utilize surgical anastomotic technology. Founded in 2012, the company aims to revolutionize surgical procedures by developing less invasive techniques for treating obesity and type 2 diabetes. G.I. Windows is focused on creating innovative solutions that not only enhance patient outcomes but also contribute to cost reduction in the healthcare system. Through its commitment to advancing surgical technology, the company seeks to establish a new category in healthcare, enabling the development of procedures that are novel and less invasive.

TRex Bio

Series B in 2024
TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Orasis Pharmaceuticals

Series D in 2024
Orasis Pharmaceuticals Ltd is focused on developing innovative treatments for presbyopia, a common age-related vision condition. Founded in 2015 and based in Herzliya, Israel, the company has developed CSF-1, a corrective eye drop designed to improve near visual acuity through pupil modulation. This product aims to enhance the quality of life for individuals with presbyopia by alleviating the need for reading glasses. CSF-1 repurposes existing, well-studied molecules to ensure its effectiveness while prioritizing safety, comfort, and ease of use for patients. By providing a noninvasive treatment option, Orasis Pharmaceuticals offers a promising solution for those struggling with the symptoms of presbyopia.

ONL Therapeutics

Series D in 2024
ONL Therapeutics is a biopharmaceutical company focused on developing innovative therapeutics to protect and improve vision in patients with retinal diseases and conditions. Founded in 2006 and headquartered in Ann Arbor, Michigan, the company specializes in creating photoreceptor protective agents that target the FAS apoptotic pathway. Its drug programs aim to safeguard photoreceptors, thereby enhancing outcomes for patients undergoing surgeries related to retinal detachment and other serious vision-threatening issues. Through its research and development efforts, ONL Therapeutics seeks to provide effective solutions for preserving sight and improving the quality of life for individuals affected by these conditions.

SpectraWAVE

Series B in 2024
Spectrawave, Inc. is a medical device company based in Waltham, Massachusetts, founded in 2017. The company specializes in developing and manufacturing optical diagnostic and therapeutic devices aimed at enhancing the diagnosis and treatment of cardiovascular diseases. One of its key innovations is a spectroscopy catheter that integrates advanced imaging technologies to improve outcomes for patients with coronary artery disease (CAD). This cutting-edge imaging system provides interventional cardiologists with crucial optical and computational insights, enabling them to identify patients and plaque formations that may pose risks for future coronary complications. Through its focus on photonics, Spectrawave aims to optimize stent interventions and improve overall patient care in the field of cardiovascular medicine.

HistoSonics

Series D in 2024
HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

Loci Orthopaedics

Series A in 2024
Loci Orthopaedics Limited, based in Upper Newcastle, Ireland, specializes in developing innovative medical technologies to address significant unmet clinical needs in orthopedics. Founded in 2017, the company focuses on creating surgical implants, particularly the InDx implant, which is designed to treat arthritis in the thumb base joint. This implant uniquely mimics the natural motions of the thumb joint, offering a less invasive and easier insertion method compared to existing surgical options. Additionally, Loci Orthopaedics is known for its Osteoanchor surface architecture, which is based on evidence-based designs, enabling clinicians to effectively address challenges in orthopedic extremities.

Asceneuron

Series C in 2024
Asceneuron SA is a biotechnology company based in Lausanne, Switzerland, founded in 2012, that focuses on discovering and developing therapeutics for neurodegenerative disorders with significant unmet medical needs. The company targets conditions such as progressive supranuclear palsy, orphan tauopathies, Alzheimer’s disease, and Parkinson’s disease. Asceneuron aims to develop orally bioavailable small molecule drugs that address both symptomatic relief and disease progression for these debilitating conditions. Tauopathies, characterized by the accumulation of tau protein deposits in the brain, are a key area of focus, as they currently lack effective treatments. With the increasing prevalence of Alzheimer's disease posing a major healthcare challenge, Asceneuron aspires to become a leading entity in the biotech sector by providing innovative and more effective therapeutic options for patients suffering from neurodegenerative diseases. The company operates as a subsidiary of Merck KGaA.

Bright Peak Therapeutics

Series C in 2024
Bright Peak Therapeutics is a biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases. The company specializes in cytokine therapeutics that enable tissue and cell-specific targeting of cytokine payloads. This approach aims to enhance the efficacy of treatments, ultimately improving patient outcomes and quality of life. By leveraging innovative immuno-cytokines, Bright Peak seeks to provide more effective therapeutic options for complex medical conditions.

Neuroene Therapeutics

Grant in 2024
Neuroene Therapeutics is a startup biotechnology company developing novel Vitamin K-based therapeutics for neurological disorders such as epilepsy. The company originated from collaborative research between Medical University of South Carolina investigators C. James Chou, Ph.D., and Sherine Chan, Ph.D., who cofounded and continue to lead Neuroene Therapeutics.

Flindr Therapeutics

Series A in 2024
Flindr Therapeutics, a private biotech company develops next-generation precision oncology treatments.

Rallybio

Post in 2024
Rallybio is a clinical-stage biopharmaceutical company focused on developing transformative therapies for patients with severe and rare disorders. Founded in 2018 and based in New Haven, Connecticut, the company is advancing its lead product candidate, RLYB211, which aims to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT), a serious condition that can lead to uncontrolled bleeding in fetuses and newborns. Rallybio's portfolio includes a range of promising product candidates targeting rare diseases across various therapeutic areas, including hematology, immuno-inflammation, maternal-fetal health, and metabolic disorders. The company's efforts are supported by a team of experienced professionals with extensive expertise in biopharma research and development.

Tempo Therapeutics

Series A in 2024
Tempo Therapeutics is a life science company focused on advancing regenerative medicine through innovative materials that are immune stealth and minimally invasive. The company harnesses immunomodulation and material science to create cell-free synthetic hydrogels designed to unlock the body's natural regenerative capabilities. By employing geometric technology, these materials can effectively control inflammation and promote accelerated healing rates. Tempo Therapeutics aims to transform medical technology by developing synthetic tissue hybrids applicable to various bodily tissues, including skin, bone, heart, and brain, while minimizing the risk of immune rejection commonly associated with traditional approaches.

Asgard Therapeutics

Series A in 2024
Asgard Therapeutics is a private biotech company focused on developing innovative cancer immunotherapies through direct cell reprogramming technologies. Emerging as a spin-off from Lund University, the company utilizes its proprietary TrojanDC technology to initiate immune responses by leveraging the unique properties of professional antigen-presenting cells. This approach aims to create efficient and personalized gene therapy products that activate robust anti-cancer immune defenses. By offering off-the-shelf solutions, Asgard Therapeutics seeks to provide new treatment options for patients suffering from cancers that are resistant to traditional therapies, thereby expanding the possibilities for effective cancer treatment.

Accent Therapeutics

Series C in 2024
Accent Therapeutics, Inc. is a biopharmaceutical company based in Lexington, Massachusetts, focused on developing small molecule therapies for oncology through the innovative field of epitranscriptomics. Founded in 2017, the company explores post-transcriptional chemical modifications of RNA, which play a crucial role in regulating proteins essential for cellular growth and differentiation. By precisely targeting RNA-modifying proteins associated with cancer, Accent Therapeutics aims to translate advanced scientific research into effective treatments for patients, ultimately providing new therapeutic options in the fight against cancer.

Nanobiotix

Post in 2023
Nanobiotix SA is a clinical-stage nanomedicine company based in Paris, France, focused on innovative cancer treatments. Founded in 2003, the company develops NanoXray products designed to enhance the effectiveness of radiotherapy by increasing the impact on tumor cells while minimizing exposure to surrounding healthy tissues. One of its primary offerings is NBTXR3, a radio-enhancer composed of hafnium oxide, which targets various solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma. In addition to NBTXR3, Nanobiotix is also involved in research programs exploring the use of magnetic particles and laser-activated nanoparticles for cancer treatment and diagnostics.

Aro Biotherapeutics

Series B in 2023
Aro Biotherapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing a novel protein drug platform known as Centyrins. Established in 2017, the company aims to enhance treatment options for oncology and immunology by creating small, non-antibody protein scaffolds. These Centyrins can be engineered as multi-specific therapeutics, enabling innovative mechanisms of action. They are designed to improve efficacy and safety profiles for patients suffering from cancer and other serious diseases, while also facilitating the targeted delivery of complex drug payloads, including nucleic acids. Aro Biotherapeutics is committed to advancing its wholly-owned pipeline of Centyrins, contributing to the field of genetic medicines.

On Target Laboratories

Series C in 2023
On Target Laboratories, LLC engages in discovering, developing, and commercializing small molecules that target specific pathological cells, when conjugated with fluorescent dyes. It offers folate and other targeting agents that target, lung, uterine, kidney, breast, colon, pancreatic, and prostate cancer cells. The company was incorporated in 2010 and is based in Northbrook, Illinois.

RefleXion Medical

Venture Round in 2023
RefleXion Medical Inc. is a medical equipment company specializing in the development of biologically-guided radiotherapy systems for cancer treatment. Its flagship innovation, the RefleXion X1 machine, is designed to deliver advanced radiation therapies such as stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS). The company's biologically-guided radiotherapy (BgRT) technology utilizes positron-emission tomography (PET) imaging data to allow tumors to continuously signal their location during treatment, enabling the possibility of treating multiple tumors in a single session, especially in cases of metastasized cancers. This real-time adaptation to the biological characteristics of tumors represents a significant advancement in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic partnerships with Telix Pharmaceuticals Limited and HealthMyne Inc. to further its mission in cancer treatment innovation.

Nanobiotix

Post in 2023
Nanobiotix SA is a clinical-stage nanomedicine company based in Paris, France, focused on innovative cancer treatments. Founded in 2003, the company develops NanoXray products designed to enhance the effectiveness of radiotherapy by increasing the impact on tumor cells while minimizing exposure to surrounding healthy tissues. One of its primary offerings is NBTXR3, a radio-enhancer composed of hafnium oxide, which targets various solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma. In addition to NBTXR3, Nanobiotix is also involved in research programs exploring the use of magnetic particles and laser-activated nanoparticles for cancer treatment and diagnostics.

Jurata Thin Film

Grant in 2023
Jurata Thin Film specializes in innovative storage technology for vaccines and biologics, aimed at enhancing their manufacturing, distribution, and delivery processes. The company has developed a unique thermostable film matrix that stabilizes biological materials, including bacterial-based vaccines and antibody-based therapeutics, allowing them to retain therapeutic efficacy even under extreme temperature conditions. This technology facilitates the long-term storage of vaccines and biologics at room temperature or higher, significantly simplifying logistics and accessibility. Additionally, the therapeutic cargo stored within this film can be rehydrated to recover the payload in an aqueous solution, offering versatile delivery options for healthcare providers.

ROME Therapeutics

Series B in 2023
ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, the company utilizes the repeatome—a previously overlooked segment of genetic material—to create novel treatment options. By identifying multiple drug targets and advancing several discovery programs, ROME Therapeutics aims to tap into this unexplored area of biology. The organization has assembled a team of experts in oncology, immunology, virology, and machine learning to lead its research and development efforts, which are designed to provide healthcare professionals with effective new treatments for patients suffering from these conditions.

Arialys Therapeutics

Seed Round in 2023
Arialys Therapeutics is a pre-clinical stage biotechnology company that specializes in neuroscience, particularly in the development of precision medicines aimed at blocking pathogenic autoantibodies in the brain. The company investigates the role of the immune system in central nervous system (CNS) health and disease, focusing on the characterization and prevalence of pathogenic auto-antibody activity. Arialys Therapeutics aims to provide advanced therapies for various CNS disorders, including neuropsychiatric conditions linked to autoimmune diseases, thereby contributing to the healthcare industry's efforts to address complex neurological challenges.

Rapport Therapeutics

Series B in 2023
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing innovative small-molecule therapies for neurological disorders. The company focuses on understanding the intricate biology of neuronal receptor complexes, which are essential for proper neuronal function and signaling. By mapping and targeting these receptor systems, Rapport Therapeutics aims to create precision medicines that can effectively address the unmet needs of patients suffering from central nervous system disorders. Through its foundational research, the company seeks to transform treatment options and improve outcomes for individuals with these challenging conditions.

CirCode

Series A in 2023
CirCode Bio is an innovative biotechnology company focusing on the development of circular RNA nucleic acid drugs.

Circular Code Biology

Series A in 2023
Ring Code Bio is a biomedical company that develops nucleic acid drugs based on a unique circular RNA technology platform.

Astraveus

Seed Round in 2023
Astraveus is transforming cell and gene therapy (CGT) manufacturing through its Lakhesys™ platform, an innovative cell foundry that leverages deep process optimization and microfluidic bioprocessors. This technology allows for the production of personalized biological therapies with minimal infrastructure requirements, ultimately reducing costs and addressing logistical challenges in the industry. By automating autologous bioproduction, the platform enhances the efficiency of transforming cells into therapeutic agents, enabling healthcare providers to scale the development and manufacturing of CGT solutions. Astraveus aims to improve patient access to these vital therapies while minimizing environmental impact.

Solenic Medical

Series A in 2023
Solenic Medical, Inc. is a medical device company founded in 2019 and based in College Station, Texas. It specializes in developing a non-invasive treatment for infected metallic implants using a technology that employs alternating magnetic fields generated by external coils. This innovative approach targets biofilm on the surfaces of medical implants, which is a significant complication in surgeries like knee and hip replacements, as well as in trauma-related procedures involving plates and rods. The technology has the potential to replace the costly and risky two-step revision surgical procedure currently used to address chronic infections in medical implants, thereby offering a safer and more effective solution for patients.

Rapport Therapeutics

Series A in 2023
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing innovative small-molecule therapies for neurological disorders. The company focuses on understanding the intricate biology of neuronal receptor complexes, which are essential for proper neuronal function and signaling. By mapping and targeting these receptor systems, Rapport Therapeutics aims to create precision medicines that can effectively address the unmet needs of patients suffering from central nervous system disorders. Through its foundational research, the company seeks to transform treatment options and improve outcomes for individuals with these challenging conditions.

Perceive Biotherapeutics

Series B in 2023
Perceive Biotherapeutics is a biotechnology company focused on developing innovative ophthalmic therapeutics aimed at treating various eye diseases. The company leverages novel protective biologies to create a diverse pipeline of therapeutic assets that target significant causes of irreversible blindness. By utilizing multiple therapeutic modalities, Perceive Biotherapeutics seeks to provide medical professionals with effective solutions for improving eye health and preventing vision loss.

HistoSonics

Convertible Note in 2022
HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

Pulmocide

Series C in 2022
Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.

SonoThera

Series A in 2022
SonoThera is a biotechnology company focused on developing non-viral genetic therapies using ultrasound technology. The company aims to create genetic medicines that address the root causes of human diseases, particularly for conditions that currently have limited or no effective treatments. By leveraging ultrasound-guided nonviral gene therapy, SonoThera seeks to enhance treatment options and improve health outcomes for millions of patients.

DocSpera

Series B in 2022
DocSpera is an integrated surgical coordination platform that enhances workflow efficiencies and patient care by streamlining synchronization across various sites and teams. Its proprietary technology automates pre-surgical coordination and facilitates real-time, secure case and image synchronization among surgeons, care teams, and device suppliers, utilizing electronic health record (EHR) data. The platform also provides real-time patient insights and operating room dashboards, enabling continuous monitoring of patients from the surgical decision point through recovery. Headquartered in Sunnyvale, California, DocSpera operates under Compliant Innovations Inc.

RefleXion Medical

Venture Round in 2022
RefleXion Medical Inc. is a medical equipment company specializing in the development of biologically-guided radiotherapy systems for cancer treatment. Its flagship innovation, the RefleXion X1 machine, is designed to deliver advanced radiation therapies such as stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS). The company's biologically-guided radiotherapy (BgRT) technology utilizes positron-emission tomography (PET) imaging data to allow tumors to continuously signal their location during treatment, enabling the possibility of treating multiple tumors in a single session, especially in cases of metastasized cancers. This real-time adaptation to the biological characteristics of tumors represents a significant advancement in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic partnerships with Telix Pharmaceuticals Limited and HealthMyne Inc. to further its mission in cancer treatment innovation.

TRex Bio

Series A in 2022
TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Rondo Therapeutics

Series A in 2022
Rondo Therapeutics is a biotechnology company focused on the discovery and development of novel bispecific antibodies aimed at activating the immune system to combat cancer. Founded in 2021 and based in Hayward, California, the company specializes in creating cancer immunotherapies specifically for solid tumor types that do not respond to conventional immune checkpoint inhibitors. By targeting areas of unmet medical need, Rondo Therapeutics enables researchers to advance innovative drug solutions in the fight against cancer.

Iterative Scopes

Series B in 2022
Iterative Scopes, Inc. is a Boston-based company founded in 2017 that specializes in developing machine learning-powered diagnostic tools aimed at assisting gastroenterologists in the prevention of colon cancer. The company focuses on providing innovative solutions for physicians and the life sciences sector, particularly in the areas of colorectal cancer and inflammatory bowel disease. By leveraging advanced technology, Iterative Scopes aims to enhance diagnostic accuracy and improve patient outcomes in these critical health areas.

Verana Health

Series E in 2022
Verana Health, Inc. is a digital health company based in San Francisco, California, that specializes in transforming healthcare data into actionable insights. Founded in 2008 and formerly known as Digisight Technologies, the company connects healthcare providers with patients through innovative solutions. Its flagship product, SightBook, is a mobile application that enables users to test their vision and share results with their physicians in real-time, facilitating timely appointments and treatments. Verana Health manages data from over 20,000 healthcare providers and 70 electronic health record systems, leveraging its AI-enhanced platform, VeraQ™, to create a robust healthcare data ecosystem. By utilizing advanced analytics on curated datasets, Verana Health supports life sciences partners in improving clinical research and enhancing patient care outcomes.

V-Wave

Series C in 2021
V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

AviadoBio

Series A in 2021
AviadoBio is focused on developing innovative gene therapies aimed at transforming the lives of individuals affected by neurodegenerative disorders, specifically frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company leverages advanced research from King's College London and the UK Dementia Research Institute to create its therapeutic platform. By integrating a comprehensive understanding of brain biology with proprietary gene therapy techniques, AviadoBio seeks to address the challenges of effectively delivering treatments to targeted areas in the brain. This approach aims to enhance the therapeutic potential of gene therapies, offering hope for halting or potentially reversing the progression of these debilitating diseases.

Mauna Kea Technologies

Post in 2021
Mauna Kea Technologies, established in 2000 and based in Paris, France, specializes in developing and marketing medical devices for cancer and other disease diagnosis and treatment. Its core product, Cellvizio, is a real-time, cellular-level imaging platform used by physicians and researchers worldwide. This platform, based on confocal laser endomicroscopy, enables precise, in vivo visualization of tissues during standard procedures, aiding in early-stage pathology detection and informed therapeutic decisions. The company generates revenue through the sale of Cellvizio products and accessories, serving customers in Europe, the Middle East, Africa, the Americas, and Asia.

Calypso Biotech

Series A in 2021
Calypso Biotech SA is an immunotherapy biotechnology company based in Plan-les-Ouates, Switzerland, founded in 2013 as a spin-off from Merck Serono. The company specializes in discovering and developing monoclonal antibodies aimed at treating immune pathologies, particularly for conditions with significant unmet medical needs, including severe gastrointestinal diseases. Calypso Biotech operates as a semi-virtual organization, leveraging a highly experienced management team with expertise in drug development. The company focuses on creating substantial value for investors through a portfolio of unique proprietary antibody candidates designed to control homeostasis and improve treatment outcomes for patients.

FlexDex

Venture Round in 2021
FlexDex Inc. is a company focused on developing minimally invasive surgery (MIS) devices. Its innovative platform technology allows for the translation of a surgeon's hand, wrist, and arm movements from outside the patient into precise movements of an end-effector inside the body, thereby enhancing the functionality of MIS instruments and endoscopes. The company collaborates with distributors to serve healthcare professionals both in the United States and internationally. Founded in 2010 and based in Brighton, Michigan, FlexDex aims to improve surgical outcomes through its advanced medical device technology.

Visus Therapeutics

Debt Financing in 2021
Visus Therapeutics is a clinical-stage company focused on developing innovative ophthalmic therapies aimed at enhancing vision for individuals globally. The company is known for its presbyopia-correcting eye drops, which are designed to provide temporary relief from the loss of near vision associated with presbyopia. Additionally, Visus Therapeutics is engaged in the development of various ophthalmic product candidates targeting conditions such as ocular surface disease, glaucoma, and age-related macular degeneration. Through its research and product offerings, the company seeks to address significant unmet needs in vision care.

Iterative Scopes

Series A in 2021
Iterative Scopes, Inc. is a Boston-based company founded in 2017 that specializes in developing machine learning-powered diagnostic tools aimed at assisting gastroenterologists in the prevention of colon cancer. The company focuses on providing innovative solutions for physicians and the life sciences sector, particularly in the areas of colorectal cancer and inflammatory bowel disease. By leveraging advanced technology, Iterative Scopes aims to enhance diagnostic accuracy and improve patient outcomes in these critical health areas.

Point Biopharma Global

Post in 2021
Point Biopharma Global Inc., established in 2019 and headquartered in Toronto, Canada, specializes in the development and commercialization of radioligand therapies for cancer treatment. The company leverages a portfolio of advanced radiopharmaceutical assets, expertise in radioisotopes like Actinium-225 and Lutetium-177, and innovative manufacturing technology. Point Biopharma Global's pipeline includes several promising candidates, such as PNT2002, PNT2004, PNT2003, and PNT2001, aiming to revolutionize theragnostic drug development and radioligand commercialization.

Ribon Therapeutics

Series C in 2021
Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on developing novel cancer therapies that target monoPARP proteins, which are essential regulators of cancer survival mechanisms. Established in 2015, Ribon is leveraging insights from its scientific founders and an experienced management team to create a proprietary drug discovery platform aimed at understanding the molecular actions and biological functions of monoPARPs. This platform enables the development of small molecule inhibitors designed to disrupt cancer cells' abilities to withstand stress, potentially leading to innovative treatments for cancer and other diseases. The company is supported by notable life science investors, positioning it for growth in the biopharmaceutical sector.

Thirty Madison

Series C in 2021
Thirty Madison, Inc. is a digital health company based in Astoria, New York, that focuses on providing specialized healthcare solutions for patients with chronic conditions. Founded in 2016, the company operates several condition-specific brands, including Keeps, which offers a subscription-based service for men’s hair loss prevention; Cove, which provides online consultations and prescriptions for migraine treatment; Picnic, targeting allergies; Facet for skin conditions; and NURX for sexual health. Each brand is designed to address the unique needs of its community, offering personalized treatments and support. Thirty Madison emphasizes a human-centered approach, empowering individuals with accessible and effective healthcare solutions tailored to their ongoing conditions.

Pulmocide

Series C in 2021
Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.

Cue

Private Equity Round in 2021
Cue Health Inc. is a healthcare technology company based in San Diego, California, specializing in the development and manufacturing of diagnostic screening devices for home use. Founded in 2010, the company offers a connected diagnostic platform known as the Cue Health Monitoring System, which allows users to conduct self-serve tests that provide lab-quality results. This platform enables individuals to track key health indicators, including inflammation, vitamin D, fertility, influenza, and testosterone, through a user-friendly device that connects to a smartphone app. The Cue app not only displays test results but also integrates data on lifestyle factors such as activity and sleep, facilitating a comprehensive view of health at a molecular level. Additionally, Cue Health provides various services for healthcare professionals, including tools for managing patient test histories and telemedicine consultations. The company's innovative approach empowers consumers and healthcare providers alike to access critical health information easily and effectively.

Mestag Therapeutics

Seed Round in 2021
Mestag Therapeutics is a biotechnology company focused on developing innovative therapies for cancer and inflammatory diseases. Utilizing a research and development platform that leverages insights into the role of activated fibroblast populations in disease, the company aims to create therapeutics that target fibroblast-mediated effects on immune cells. This approach is designed to enhance the medical industry's ability to combat and potentially cure rare and life-threatening conditions. Through its work, Mestag Therapeutics seeks to contribute meaningful advancements in the treatment landscape for these challenging diseases.

Sunday2Sunday

Series A in 2021
Sunday2Sunday is an emerging textured hair care company that focuses on bringing ingredients and products to its customer's doorstep. It specializes in the fields of beauty, healthcare, and consumer goods. It was founded in 2019 and headquartered in Brooklyn, New York.

Visus Therapeutics

Series A in 2021
Visus Therapeutics is a clinical-stage company focused on developing innovative ophthalmic therapies aimed at enhancing vision for individuals globally. The company is known for its presbyopia-correcting eye drops, which are designed to provide temporary relief from the loss of near vision associated with presbyopia. Additionally, Visus Therapeutics is engaged in the development of various ophthalmic product candidates targeting conditions such as ocular surface disease, glaucoma, and age-related macular degeneration. Through its research and product offerings, the company seeks to address significant unmet needs in vision care.

TechsoMed

Series B in 2021
TechsoMed is an Israeli medical device company focused on developing ultrasound-based real-time monitoring systems specifically for thermal ablation procedures. This technology addresses the high failure rates associated with these minimally invasive treatments, which are used in various applications, including tumor destruction, heart arrhythmia management, and blood pressure regulation. By providing real-time monitoring and control of tissue destruction, TechsoMed's system enhances the effectiveness of ablation procedures, offering significant benefits to patients, physicians, and insurance companies. The integration of their imaging and analysis unit with standard ultrasound devices allows physicians to better predict the progression of tissue destruction, thereby improving treatment outcomes in a market that has significant growth potential.

Paige

Series C in 2021
Paige, founded in 2017 by Thomas Fuchs and colleagues from Memorial Sloan Kettering Cancer Center, specializes in computational pathology products that enhance cancer diagnostics. The company has developed a platform utilizing advanced deep learning algorithms to improve diagnostic stratification and cancer detection, particularly for breast and prostate cancers. This innovative technology aims to empower patients and their care teams to make informed treatment decisions by providing pathologists with critical insights for more accurate diagnoses. Paige's user-friendly platform minimizes the burden on IT resources while ensuring patient safety and data privacy. As a pioneer in the field, Paige has achieved FDA breakthrough designation for its computational pathology products, positioning itself at the forefront of transforming pathology workflows and increasing diagnostic confidence.

ONL Therapeutics

Series B in 2020
ONL Therapeutics is a biopharmaceutical company focused on developing innovative therapeutics to protect and improve vision in patients with retinal diseases and conditions. Founded in 2006 and headquartered in Ann Arbor, Michigan, the company specializes in creating photoreceptor protective agents that target the FAS apoptotic pathway. Its drug programs aim to safeguard photoreceptors, thereby enhancing outcomes for patients undergoing surgeries related to retinal detachment and other serious vision-threatening issues. Through its research and development efforts, ONL Therapeutics seeks to provide effective solutions for preserving sight and improving the quality of life for individuals affected by these conditions.

Taza Aya

Grant in 2020
Taza Aya, headquartered in Ann Arbor, Michigan, specializes in non-thermal plasma technologies designed to neutralize airborne pathogens. The company's core product is a wearable device, intended for integration into building-scale HVAC systems, which aims to improve respiratory protection and enhance safety in workplaces and public spaces by addressing airborne pathogens.

Datavant

Series B in 2020
Datavant, Inc. is a health data platform company based in San Francisco, California, founded in 2017. The company specializes in aggregating and analyzing biomedical data using machine learning to enhance the efficiency of drug development. It focuses on improving the clinical trial process by employing artificial intelligence and organizing healthcare data to derive actionable insights for trial design and interpretation. By facilitating secure and accessible data connectivity, Datavant enables over 60 million healthcare records to be exchanged among thousands of organizations, including more than 70,000 hospitals and clinics. The company serves the clinical development and commercial pharmaceutical sectors, as well as researchers, and aims to improve patient outcomes while protecting patient privacy through its innovative platform.

Syndesi Therapeutics

Series A in 2020
Syndesi Therapeutics SA is a biopharmaceutical company based in Louvain-la-Neuve, Belgium, founded in 2018. The company focuses on developing drug molecules that modulate the synaptic vesicle protein SV2A, which is crucial for synaptic transmission—the process that facilitates communication between neurons in the brain. By regulating this transmission, Syndesi aims to create effective treatments for Alzheimer’s Disease and other cognitive impairment disorders. The company holds an exclusive license to its innovative platform technology from UCB, a leader in SV2A research. Through its efforts, Syndesi Therapeutics seeks to provide healthcare providers with advanced therapeutic options for managing these challenging conditions.

V-Wave

Series C in 2020
V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

XWPharma

Series C in 2020
XWPharma is a neuroscience biotechnology company based in the Bay Area, California, focused on developing innovative therapeutics for sleep, neuropsychiatric, and other neglected central nervous system (CNS) disorders. The company specializes in drug discovery and vaccine development, aiming to address underserved conditions that affect patients' mental health and sleep quality. Through its research, XWPharma seeks to create new medications that can help individuals overcome insomnia and related disorders, ultimately improving their overall well-being.

Sunday2Sunday

Seed Round in 2020
Sunday2Sunday is an emerging textured hair care company that focuses on bringing ingredients and products to its customer's doorstep. It specializes in the fields of beauty, healthcare, and consumer goods. It was founded in 2019 and headquartered in Brooklyn, New York.

Aetion

Series B in 2020
Aetion, Inc. is a healthcare analytics company that specializes in real-world evidence (RWE) and outcomes-based analytics solutions. Founded in 2012 and based in New York City, Aetion develops the Aetion Evidence Platform, which leverages everyday clinical and financial interactions within the healthcare system to generate critical insights about the effectiveness and value of medical treatments. This platform serves a diverse clientele, including life sciences companies, payers, providers, medical device manufacturers, and academic institutions, allowing them to analyze data from various sources such as claims, electronic health records, registries, and clinical trials. Aetion’s patented rapid-cycle analytics technology facilitates real-time collaboration among stakeholders, enabling them to make informed decisions and optimize patient care. The company has formed strategic partnerships with leading organizations, including McKesson, to enhance its offerings and expand its reach in the healthcare sector.

G.I. Windows

Series A in 2020
G.I. Windows, Inc. is a clinical-stage company based in West Bridgewater, Massachusetts, specializing in the manufacture of medical devices that utilize surgical anastomotic technology. Founded in 2012, the company aims to revolutionize surgical procedures by developing less invasive techniques for treating obesity and type 2 diabetes. G.I. Windows is focused on creating innovative solutions that not only enhance patient outcomes but also contribute to cost reduction in the healthcare system. Through its commitment to advancing surgical technology, the company seeks to establish a new category in healthcare, enabling the development of procedures that are novel and less invasive.

ImmPACT Bio

Series A in 2020
ImmPACT Bio USA Inc. is a cell therapy company focused on developing engineered T-cells specifically designed to target and treat solid tumors. By utilizing advanced technology, the company aims to create chimeric antigen receptor (CAR) T-cell therapies that exhibit tumor specificity, allowing them to induce cytotoxicity only when interacting with tumor cells while sparing healthy tissues. This selective targeting mitigates the safety risks commonly associated with existing CAR-T therapies, providing a promising approach to cancer treatment that enhances efficacy and reduces potential harm to noncancerous cells.

Thirty Madison

Series B in 2020
Thirty Madison, Inc. is a digital health company based in Astoria, New York, that focuses on providing specialized healthcare solutions for patients with chronic conditions. Founded in 2016, the company operates several condition-specific brands, including Keeps, which offers a subscription-based service for men’s hair loss prevention; Cove, which provides online consultations and prescriptions for migraine treatment; Picnic, targeting allergies; Facet for skin conditions; and NURX for sexual health. Each brand is designed to address the unique needs of its community, offering personalized treatments and support. Thirty Madison emphasizes a human-centered approach, empowering individuals with accessible and effective healthcare solutions tailored to their ongoing conditions.

Vor Biopharma

Series B in 2020
Vor Biopharma, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing engineered hematopoietic stem cell (eHSC) therapies for cancer treatment. The company's lead product candidate, VOR33, is designed specifically for the treatment of acute myeloid leukemia (AML) and is currently in preclinical development. VOR33 eHSCs are engineered to lack CD33, a protein commonly expressed by AML cells, allowing for selective targeting of the cancer without harming normal cells. This innovative approach seeks to minimize the toxicities associated with traditional immunotherapies, which often affect both cancerous and healthy tissues. By protecting healthy stem cells from depletion while generating functional immune cells, Vor Biopharma aims to enhance therapeutic outcomes for patients with hematological malignancies.

Cue

Series C in 2020
Cue Health Inc. is a healthcare technology company based in San Diego, California, specializing in the development and manufacturing of diagnostic screening devices for home use. Founded in 2010, the company offers a connected diagnostic platform known as the Cue Health Monitoring System, which allows users to conduct self-serve tests that provide lab-quality results. This platform enables individuals to track key health indicators, including inflammation, vitamin D, fertility, influenza, and testosterone, through a user-friendly device that connects to a smartphone app. The Cue app not only displays test results but also integrates data on lifestyle factors such as activity and sleep, facilitating a comprehensive view of health at a molecular level. Additionally, Cue Health provides various services for healthcare professionals, including tools for managing patient test histories and telemedicine consultations. The company's innovative approach empowers consumers and healthcare providers alike to access critical health information easily and effectively.

HistoSonics

Series C in 2020
HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

Gatt

Series B in 2020
GATT Technologies BV, established in 2011 and headquartered in Nijmegen, the Netherlands, specializes in developing innovative medical devices. The company focuses on creating synthetic surgical hemostat and sealant products designed to control severe bleeding and organ leakages during surgical procedures. Their product portfolio includes GATT-Patch, a hemostatic sealing patch for general surgery; GATT-Tape, an adhesive tape for preventing intestinal anastomotic leakage; GATT-Spray, an elastic sealant for general surgery; and GATT-Powder, a hemostatic sealing powder. These products are based on a patented synthetic technology, aiming to address challenging surgical bleeding and leakage issues.

RefleXion Medical

Series D in 2020
RefleXion Medical Inc. is a medical equipment company specializing in the development of biologically-guided radiotherapy systems for cancer treatment. Its flagship innovation, the RefleXion X1 machine, is designed to deliver advanced radiation therapies such as stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS). The company's biologically-guided radiotherapy (BgRT) technology utilizes positron-emission tomography (PET) imaging data to allow tumors to continuously signal their location during treatment, enabling the possibility of treating multiple tumors in a single session, especially in cases of metastasized cancers. This real-time adaptation to the biological characteristics of tumors represents a significant advancement in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic partnerships with Telix Pharmaceuticals Limited and HealthMyne Inc. to further its mission in cancer treatment innovation.

OrthoSpin

Series B in 2020
OrthoSpin Limited, founded in 2014 and based in Misgav, Israel, specializes in the development of an innovative robotic external fixation system designed to enhance treatment for patients with bone injuries and limb deformities. The company’s dynamic external fixators offer a significant improvement over traditional systems, which are often cumbersome and painful. OrthoSpin’s system features a lightweight motorized strut and a control box integrated into a circular hexapod fixation frame, allowing for automatic and continuous pre-programmed adjustments without requiring patient involvement. This smart system not only ensures adherence to prescribed treatment plans but also enables real-time monitoring of patient progress through proprietary software. By facilitating timely adjustments to treatment schedules, OrthoSpin aims to reduce complications and improve clinical outcomes for orthopedic patients, thereby accelerating their recovery process.

AviadoBio

Seed Round in 2020
AviadoBio is focused on developing innovative gene therapies aimed at transforming the lives of individuals affected by neurodegenerative disorders, specifically frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company leverages advanced research from King's College London and the UK Dementia Research Institute to create its therapeutic platform. By integrating a comprehensive understanding of brain biology with proprietary gene therapy techniques, AviadoBio seeks to address the challenges of effectively delivering treatments to targeted areas in the brain. This approach aims to enhance the therapeutic potential of gene therapies, offering hope for halting or potentially reversing the progression of these debilitating diseases.

Mauna Kea Technologies

Post in 2019
Mauna Kea Technologies, established in 2000 and based in Paris, France, specializes in developing and marketing medical devices for cancer and other disease diagnosis and treatment. Its core product, Cellvizio, is a real-time, cellular-level imaging platform used by physicians and researchers worldwide. This platform, based on confocal laser endomicroscopy, enables precise, in vivo visualization of tissues during standard procedures, aiding in early-stage pathology detection and informed therapeutic decisions. The company generates revenue through the sale of Cellvizio products and accessories, serving customers in Europe, the Middle East, Africa, the Americas, and Asia.

ProteKt Therapeutics

Venture Round in 2019
ProteKt Therapeutics is a drug development company focused on creating potent and selective oral inhibitors of the kinase PKR to address neurodegenerative and neuroinflammatory diseases. The company has successfully developed a series of novel molecules through innovative computational methods, followed by validation in clinically relevant assays. These inhibitors aim to improve memory consolidation and enhance long-term memory in patients suffering from these conditions. ProteKt Therapeutics has raised $4 million in a pre-A funding round and is a graduate of the FutuRx accelerator, which supports emerging biotechnology ventures.

X-Vax

Series A in 2019
X-Vax Technology is a biotechnology company based in Jupiter, Florida, established in 2015. The company specializes in the preclinical and clinical development of vaccines designed to combat mucosal infections caused by pathogens such as herpes, influenza, tuberculosis, and HIV, which impact millions globally. X-Vax is advancing a herpes vaccine candidate based on a genetically modified HSV-2 virus that lacks glycoprotein D. This innovative approach aims to prevent infections from both herpes type 1 and type 2 by inducing antibodies that facilitate antibody-dependent cell-mediated killing, thereby creating a robust immune response against these viruses.

Cara Care

Series A in 2019
Cara Care is a digital health platform focused on improving gut health through an app designed for patients with chronic gastrointestinal issues. The application enables users to track their dietary habits, including custom dishes and food items from an extensive database, while also recording symptoms such as pain, bloating, and emotional states. This comprehensive approach allows individuals to identify patterns and correlations between their diet and digestive health, empowering them to take control of their well-being. With a user base exceeding 700,000 patients globally, Cara Care combines behavioral, microbial, and nutritional data to offer a holistic alternative to traditional medication for digestive disorders.

Blackthorn Therapeutics

Series B in 2019
Blackthorn Therapeutics, based in South San Francisco, California, is a clinical-stage biopharmaceutical company focused on developing precision medicine for neurobehavioral disorders. Founded in 2013, the company utilizes a proprietary computational platform that integrates advances in computational and clinical neuroscience to better understand the relationship between brain function and behavior. By targeting dysfunctional brain circuits, Blackthorn aims to address longstanding challenges in drug discovery and development. The company’s approach involves identifying novel therapeutic targets, small molecule drug candidates, and biologically-based patient subgroups that are most likely to benefit from treatment, thereby enhancing the precision of therapeutic interventions in the central nervous system.

TechsoMed

Venture Round in 2019
TechsoMed is an Israeli medical device company focused on developing ultrasound-based real-time monitoring systems specifically for thermal ablation procedures. This technology addresses the high failure rates associated with these minimally invasive treatments, which are used in various applications, including tumor destruction, heart arrhythmia management, and blood pressure regulation. By providing real-time monitoring and control of tissue destruction, TechsoMed's system enhances the effectiveness of ablation procedures, offering significant benefits to patients, physicians, and insurance companies. The integration of their imaging and analysis unit with standard ultrasound devices allows physicians to better predict the progression of tissue destruction, thereby improving treatment outcomes in a market that has significant growth potential.

Cala Health

Series C in 2019
Cala Health, Inc. is a bioelectronic medicine company based in Burlingame, California, founded in 2013. It specializes in developing wearable neuromodulation therapies aimed at treating chronic diseases. The company's flagship product, Cala Trio, is a non-invasive prescription therapy designed to provide transient relief from hand tremors in adults with essential tremor. By integrating advancements in neuroscience and technology, Cala Health focuses on delivering individualized peripheral nerve stimulation. In addition to its work on essential tremor, the company is also developing therapies for other neurological conditions, including Parkinson's disease, as well as applications in psychiatry, cardiology, and autoimmune disorders.

Fusion Pharmaceuticals

Series B in 2019
Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company headquartered in Hamilton, Canada, specializing in the development of radiopharmaceuticals as precision medicines for challenging cancers. The company employs its proprietary Targeted Alpha Therapies platform and Fast-Clear linker technology to connect alpha particle-emitting isotopes to antibodies, enabling the selective delivery of therapeutic agents to tumors. Fusion's lead product candidate, FPI-1434, is currently undergoing Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Additionally, the company is exploring the use of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors in preclinical studies to enhance anti-tumor activity. Fusion is also advancing another product candidate, FPI-1966, into clinical development for head and neck and bladder cancers that express fibroblast growth factor receptor. Founded in 2014 as a spinout of the Centre for Probe Development and Commercialization, Fusion aims to transform how cancers are treated through innovative radiochemistry techniques.

Vor Biopharma

Series A in 2019
Vor Biopharma, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing engineered hematopoietic stem cell (eHSC) therapies for cancer treatment. The company's lead product candidate, VOR33, is designed specifically for the treatment of acute myeloid leukemia (AML) and is currently in preclinical development. VOR33 eHSCs are engineered to lack CD33, a protein commonly expressed by AML cells, allowing for selective targeting of the cancer without harming normal cells. This innovative approach seeks to minimize the toxicities associated with traditional immunotherapies, which often affect both cancerous and healthy tissues. By protecting healthy stem cells from depletion while generating functional immune cells, Vor Biopharma aims to enhance therapeutic outcomes for patients with hematological malignancies.

Memebox

Series D in 2019
Memebox Corporation is an online retailer specializing in beauty care products, focusing particularly on Asian beauty trends and culture. Founded in 2012 and based in San Francisco, the company offers a diverse range of skincare items, including cleansers, toners, sheet masks, serums, creams, and body care products. In addition to skincare, Memebox provides a wide array of makeup products, such as foundations, powders, eye makeup, and lip care. The company is known for its ability to forecast beauty trends and create private labels inspired by K-beauty, catering to customers in the United States, China, Korea, and internationally.

Ribon Therapeutics

Series B in 2019
Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on developing novel cancer therapies that target monoPARP proteins, which are essential regulators of cancer survival mechanisms. Established in 2015, Ribon is leveraging insights from its scientific founders and an experienced management team to create a proprietary drug discovery platform aimed at understanding the molecular actions and biological functions of monoPARPs. This platform enables the development of small molecule inhibitors designed to disrupt cancer cells' abilities to withstand stress, potentially leading to innovative treatments for cancer and other diseases. The company is supported by notable life science investors, positioning it for growth in the biopharmaceutical sector.

MultiScale Health Networks

Venture Round in 2018
MultiScale Health Networks LLC is a Seattle-based company established in 2012 that specializes in developing and marketing a cloud-based data platform for the healthcare industry. Its flagship product, MultiScale Hive, enables real-time access to electronic health record (EHR) data, facilitating enhanced communication and collaboration among multidisciplinary teams. The platform aggregates and optimizes operational intelligence from emergency departments, allowing healthcare providers to address issues as they arise. By leveraging data mining, machine learning, and semantic data technology, MultiScale Health Networks aims to improve care delivery outcomes, enhance patient engagement, and increase operational efficiency while reducing costs and latency in healthcare delivery.

Carrot

Venture Round in 2018
Carrot Inc. is a company based in Redwood City, California, that specializes in smoking cessation through its application, Pivot. Founded in 2015, Carrot offers a unique six-stage program that engages smokers early in their journey without imposing pressure to quit. The program begins by fostering awareness of smoking habits and enhancing confidence in the smoker's ability to change. For those who choose to pursue cessation, Pivot assists users in creating and implementing a personalized quit plan, supported by one-on-one coaching until they achieve stability in their quit journey. This approach emphasizes self-motivation and personal commitment, distinguishing Carrot's service in the field of smoking cessation.

CuraSen Therapeutics

Series A in 2018
CuraSen Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases. The company specializes in small molecule drugs that target a novel mechanism in the brain, aiming to restore function, improve symptoms, and modify the progression of conditions such as Parkinson's disease, Alzheimer's disease, and less common orphan neurodegenerative disorders. Founded in 2016, CuraSen Therapeutics is headquartered in Los Altos, California.

PhaseBio

Series D in 2018
PhaseBio Pharmaceuticals, Inc., established in 2002 and based in Malvern, Pennsylvania, is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for cardiopulmonary diseases. Its primary focus is on PB2452, a reversal agent for the antiplatelet drug ticagrelor, currently in Phase III trials for managing uncontrolled bleeding events or urgent surgeries. Additionally, PhaseBio is developing PB1046, a fusion protein in Phase IIb trials for treating pulmonary arterial hypertension, and PB6440, an oral agent for resistant hypertension. The company's proprietary technology, elastin-like polypeptides (ELPs), enhances the stability, bioavailability, and efficacy of proteins and peptides, aiming to improve patient outcomes and reduce side effects.

OrthoSpin

Venture Round in 2018
OrthoSpin Limited, founded in 2014 and based in Misgav, Israel, specializes in the development of an innovative robotic external fixation system designed to enhance treatment for patients with bone injuries and limb deformities. The company’s dynamic external fixators offer a significant improvement over traditional systems, which are often cumbersome and painful. OrthoSpin’s system features a lightweight motorized strut and a control box integrated into a circular hexapod fixation frame, allowing for automatic and continuous pre-programmed adjustments without requiring patient involvement. This smart system not only ensures adherence to prescribed treatment plans but also enables real-time monitoring of patient progress through proprietary software. By facilitating timely adjustments to treatment schedules, OrthoSpin aims to reduce complications and improve clinical outcomes for orthopedic patients, thereby accelerating their recovery process.

S-Biomedic

Series A in 2018
S-Biomedic is a biotech company based in Beerse, Belgium, specializing in live probiotic cosmetics aimed at improving skin health. The company develops innovative products that target the skin microbiome, which consists of a diverse community of bacteria that can influence various skin conditions, including acne, eczema, rosacea, and signs of aging. Utilizing advanced modulation-based technology, S-Biomedic selects beneficial bacteria to create formulations that restore balance to the skin's microbiome. This approach not only addresses existing skin issues but also enhances overall skin health and beauty. By bridging advancements in microbiology and dermatology, S-Biomedic offers therapeutic solutions for both dermatological and cosmetic applications.

Zebra Medical Vision

Series C in 2018
Zebra Medical Vision Ltd. is a company that develops an imaging analytics platform aimed at enhancing patient care in healthcare institutions. Founded in 2014 and based in Shefayim, Israel, the platform utilizes advanced learning and computer vision algorithms to assist clinicians in identifying patients at risk of various diseases. This technology supports healthcare providers in implementing effective risk management and preventative care strategies. Zebra Medical Vision also supplies tools and datasets for machine-learning researchers, facilitating the rapid development of decision support tools and diagnostic solutions. The company has established strategic partnerships with organizations such as USARAD Holdings and TELUS Ventures, and has secured a total of $52 million in funding from notable investors, including Khosla Ventures and Nvidia. Its AI-driven products are FDA cleared and are utilized in hospitals across multiple regions, including the U.S., Europe, Australia, India, and Latin America, positioning Zebra Medical Vision as a leader in the field of medical imaging and analytics.

NeuroVision

Series C in 2018
NeuroVision Imaging LLC, established in 2010 and based in Sacramento, California, specializes in developing digital imaging and diagnostic solutions for Alzheimer's disease and eye care markets. The company's core focus is the development of diagnostic tests and biomarkers for the early detection and monitoring of amyloid pathology related to Alzheimer's disease. NeuroVision has pioneered a retinal imaging technology that uses low-cost, non-invasive eye imaging to measure retinal autofluorescence, aiming to assess the accumulation of amyloid-beta plaque in the brain. Additionally, the company offers data aggregation services, analysis, biostatistics, and machine learning algorithms to analyze large repositories of images and other biomarker data, furthering the understanding and prediction capabilities for neurodegenerative diseases. NeuroVision serves clients in the United States and internationally.

Syndesi Therapeutics

Series A in 2018
Syndesi Therapeutics SA is a biopharmaceutical company based in Louvain-la-Neuve, Belgium, founded in 2018. The company focuses on developing drug molecules that modulate the synaptic vesicle protein SV2A, which is crucial for synaptic transmission—the process that facilitates communication between neurons in the brain. By regulating this transmission, Syndesi aims to create effective treatments for Alzheimer’s Disease and other cognitive impairment disorders. The company holds an exclusive license to its innovative platform technology from UCB, a leader in SV2A research. Through its efforts, Syndesi Therapeutics seeks to provide healthcare providers with advanced therapeutic options for managing these challenging conditions.

On Target Laboratories

Series B in 2017
On Target Laboratories, LLC engages in discovering, developing, and commercializing small molecules that target specific pathological cells, when conjugated with fluorescent dyes. It offers folate and other targeting agents that target, lung, uterine, kidney, breast, colon, pancreatic, and prostate cancer cells. The company was incorporated in 2010 and is based in Northbrook, Illinois.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.